The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This
South Korea’s Ministry of Food and Drug Safety (MFDS) granted Orphan Drug Designation to equecabtagene autoleucel (Fucaso; eque-cel) for adults with relapsed or
The US Food and Drug Administration (FDA) denied the supplemental Biologics License Application (sBLA) for glofitamab combined with gemcitabine and oxaliplatin (GemOx) for
Meet Alice Mims, MD, a professor at The Ohio State University and senior medical director of the BeatAML study. Dr. Mims discusses venetoclax’s
A Finnish study found that patients with diffuse large B-cell lymphoma (DLBCL) who have low income levels have significantly worse survival outcomes.
Long-term follow-up from the CARTITUDE-1 study showed that 33% of heavily pretreated patients with multiple myeloma (MM) were in remission for 5 or
SOHO President Phillip Scheinberg, MD, PhD, head of the Division of Hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, wrote
A study found that low baseline vitamin D is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL); however, supplementation
Phil Scheinberg, MD, PhD, chief of hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, shares his first impressions of
A post-hoc analysis of pooled data from the IMerge trial found that patients with low-risk myelodysplastic syndromes (MDS) who were ineligible for erythropoiesis-stimulating
